BPMC:NGS-Blueprint Medicines Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 87.22

Change

0.00 (0.00)%

Market Cap

USD 1.00B

Volume

0.36M

Analyst Target

USD 97.36
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.35 (+0.33%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+2.96 (+0.41%)

USD 84.94B
ARGX argenx NV ADR

+1.13 (+0.18%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+0.66 (+0.28%)

USD 31.66B
BGNE BeiGene Ltd

N/A

USD 20.24B
UTHR United Therapeutics Corporatio..

-3.89 (-1.08%)

USD 16.18B
MRNA Moderna Inc

+0.18 (+0.43%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.05 (+0.19%)

USD 15.05B
INCY Incyte Corporation

+0.10 (+0.14%)

USD 13.52B
SMMT Summit Therapeutics PLC

-0.11 (-0.60%)

USD 13.43B

ETFs Containing BPMC

WDNA:LSE WisdomTree BioRevolution .. 2.71 % 0.00 %

+0.01 (+1.17%)

N/A
WDNA WisdomTree BioRevolution .. 2.53 % 0.00 %

+0.17 (+1.17%)

USD 2.18M
WBIO:LSE WisdomTree BioRevolution .. 2.45 % 0.00 %

-2.60 (1.17%)

USD 0.45M
WRNA:XETRA WisdomTree BioRevolution .. 2.35 % 0.00 %

-0.06 (1.17%)

USD 2.77M
CNCR Loncar Cancer Immunothera.. 1.70 % 0.79 %

+0.43 (+1.17%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -1.71% 67% D+ 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.71% 67% D+ 43% F
Trailing 5 Years  
Capital Gain 7.96% 79% B- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.96% 79% B- 50% F
Average Annual (5 Year Horizon)  
Capital Gain 16.23% 62% D 69% C-
Dividend Return 16.23% 62% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.34% 64% D 38% F
Risk Adjusted Return 32.25% 86% B+ 64% D
Market Capitalization 1.00B 96% N/A 89% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.36 30% 49%
Price/Book Ratio 18.90 9% 7%
Price / Cash Flow Ratio -13.55 84% 86%
Price/Free Cash Flow Ratio -11.22 92% 90%
Management Effectiveness  
Return on Equity -49.66% 68% 32%
Return on Invested Capital -67.85% 43% 18%
Return on Assets -14.97% 82% 30%
Debt to Equity Ratio 159.66% 13% 14%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.